Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in...
PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
PARIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
PARIS, May 09, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a...
PARIS, May 04, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...
PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a...
Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and...
Launch of capital increase of approximately €15 million for institutional investors with cancellation of the...
PARIS, March 31, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...
PARIS, March 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a...
PARIS, March 14, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a...
Quantum Genomics will receive up to $20 M in upfront, development and sales milestone payments as well as...
Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future salesTeva...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.